LFB BIOMEDICAMENTS : revenue, balance sheet and financial ratios

LFB BIOMEDICAMENTS is a French company founded 19 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in LES ULIS (91940), this company of category ETI shows in 2024 a revenue of 492.1 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - LFB BIOMEDICAMENTS (SIREN 491371167)
Indicator 2024 2023 2022 2019 2018 2017 2016
Revenue 492 129 699 € 468 703 455 € 466 630 300 € 312 298 508 € 325 031 116 € 424 460 918 € 456 788 401 €
Net income -187 798 117 € -141 029 892 € -97 716 889 € -91 312 131 € -82 485 078 € -32 126 205 € 34 059 957 €
EBITDA -76 782 856 € -79 867 986 € -19 402 626 € -46 436 217 € 657 990 255 € 68 267 033 € 109 505 625 €
Net margin -38.2% -30.1% -20.9% -29.2% -25.4% -7.6% 7.5%

Revenue and income statement

En 2024, LFB BIOMEDICAMENTS alcanza unos ingresos de 492.1 M€. Los ingresos crecen positivamente durante 7 años (TCAC: +0.9%). Vs 2023: +5%. Tras deducir el consumo (235.4 M€), el margen bruto se sitúa en 256.7 M€, es decir, una tasa del 52%. El EBITDA alcanza -76.8 M€, representando el -15.6% de los ingresos. Un EBITDA negativo significa que las operaciones no cubren los gastos corrientes. El resultado neto es negativo en -187.8 M€ (-38.2% de los ingresos).

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

492 129 699 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

256 722 810 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-76 782 856 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-143 974 340 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

-187 798 117 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

-15.6%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

El ratio de endeudamiento (= Deuda financiera / Fondos propios x 100) se sitúa en -431%. Este nivel muy bajo refleja una estructura financiera sólida. La autonomía financiera (= Fondos propios / Total activo x 100) alcanza el -23%. Baja autonomía: la empresa depende fuertemente de financiación externa.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

-430.614%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

-23.322%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

-30.394%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

-8.394

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

73.9%

Solvency indicators evolution
LFB BIOMEDICAMENTS

Sector positioning

Ratio de endeudamiento
-430.61 2024
2022
2023
2024
Q1: 0.0
Med: 5.92
Q3: 43.75
Excelente -88 pts over 3 years

En 2024, el ratio de endeudamiento de LFB BIOMEDICAMENTS (-430.61) se sitúa en el 25% más bajo del sector, lo cual es positivo. Este ratio mide el peso de la deuda en relación con el patrimonio. Un ratio bajo indica una estructura financiera sólida con poca dependencia de los acreedores.

Autonomía financiera
-23.32% 2024
2022
2023
2024
Q1: 28.05%
Med: 51.52%
Q3: 72.2%
Vigilar

En 2024, el autonomía financiera de LFB BIOMEDICAMENTS (-23.3%) se sitúa en el 25% más bajo del sector. Este ratio representa la parte del patrimonio en la financiación total. Baja autonomía puede limitar la capacidad de inversión y aumentar la vulnerabilidad.

Capacidad de reembolso
-8.39 ans 2024
2022
2023
2024
Q1: 0.0 ans
Med: 0.01 ans
Q3: 1.74 ans
Excelente

En 2024, el capacidad de reembolso de LFB BIOMEDICAMENTS (-8.4 an) se sitúa en el 25% más bajo del sector, lo cual es positivo. Este ratio indica el número de años necesarios para pagar la deuda con flujo de caja. Una capacidad corta refleja deuda controlada y buena generación de efectivo.

Liquidity ratios

El ratio de liquidez se sitúa en 199.97. La empresa tiene 2€ de activos líquidos por cada 1€ de deuda a corto plazo.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

199.971

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-60.034

Liquidity indicators evolution
LFB BIOMEDICAMENTS

Sector positioning

Ratio de liquidez
199.97 2024
2022
2023
2024
Q1: 120.09
Med: 209.86
Q3: 363.93
Average +12 pts over 3 years

En 2024, el ratio de liquidez de LFB BIOMEDICAMENTS (199.97) se sitúa por debajo de la mediana del sector. Este ratio mide la capacidad de cubrir deuda a corto plazo con activos corrientes. Una mejora fortalecería la posición competitiva.

Cobertura de intereses
-60.03x 2024
2022
2023
2024
Q1: 0.0x
Med: 1.78x
Q3: 10.15x
Vigilar

En 2024, el cobertura de intereses de LFB BIOMEDICAMENTS (-60.0x) se sitúa en el 25% más bajo del sector. Este ratio indica cuántas veces el resultado operativo cubre los gastos de intereses. Baja cobertura puede indicar fragilidad ante variaciones de tipos o ingresos.

Working capital requirement (WCR) and payment terms

El fondo de maniobra operativo (FM) mide el desfase temporal de tesorería. Plazo medio de cobro a clientes: 29 días. Plazo proveedores: 61 días. Excelente situación: los proveedores financian 32 días del ciclo operativo. La rotación de existencias es de 314 días. Este alto nivel inmoviliza tesorería y potencialmente crea riesgo de obsolescencia. El FM representa 252 días de ingresos. En 2016-2024, el FM aumentó en +125%.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

344 451 419 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

29 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

61 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

314 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

252 j

WCR and payment terms evolution
LFB BIOMEDICAMENTS

Positioning of LFB BIOMEDICAMENTS in its sector

Comparison with sector Fabrication de préparations pharmaceutiques

Similar companies (Fabrication de préparations pharmaceutiques)

Compare LFB BIOMEDICAMENTS with other companies in the same sector:

Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques

Frequently asked questions about LFB BIOMEDICAMENTS

What is the revenue of LFB BIOMEDICAMENTS ?

The revenue of LFB BIOMEDICAMENTS in 2024 is 492.1 M€.

Is LFB BIOMEDICAMENTS profitable?

LFB BIOMEDICAMENTS recorded a net loss in 2024.

Where is the headquarters of LFB BIOMEDICAMENTS ?

The headquarters of LFB BIOMEDICAMENTS is located in LES ULIS (91940), in the department Essonne.

Where to find the tax return of LFB BIOMEDICAMENTS ?

The tax return of LFB BIOMEDICAMENTS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does LFB BIOMEDICAMENTS operate?

LFB BIOMEDICAMENTS operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.